CureMetrix and Therapixel Partner to Deliver Dual-Purpose AI for Mammography

CureMetrix, a leader in artificial intelligence (AI) solutions for mammography, has announced a strategic partnership with Therapixel Inc., the company behind MammoScreen—an advanced AI system for breast cancer detection. The collaboration aims to integrate CureMetrix’s cmAngio® with MammoScreen to enhance clinical value and operational efficiency for radiologists and healthcare systems.

cmAngio is the first and only FDA-cleared AI software designed to detect and localize breast arterial calcifications (BAC) on screening mammograms. These calcifications, often overlooked, can serve as a marker for cardiovascular risk in women. cmAngio flags and highlights BAC on routine mammograms, enabling radiologists to refer patients for further cardiovascular evaluation when appropriate.

MammoScreen assists radiologists by analyzing 2D and 3D mammograms, along with prior imaging, to detect breast cancer. The AI platform offers a streamlined scoring system, image quality feedback, patient history alerts, and automated draft reporting—all aimed at improving efficiency, reducing reader fatigue, and enhancing consistency across interpretations.

Together, cmAngio and MammoScreen offer a comprehensive solution that enhances both breast cancer screening and cardiovascular risk assessment, effectively transforming mammography into a dual-purpose exam.

“This partnership aligns two innovators committed to transforming women’s health,” said Kevin Harris, President of CureMetrix. “cmAngio is live at hundreds of sites across the US and has been offered to almost 1 million women. By integrating cmAngio with Therapixel’s MammoScreen, we are broadening our reach, unifying installation for customers, and helping radiologists deliver deeper, data-driven insights that can improve outcomes for patients.”

“We’re proud to partner with CureMetrix to bring even more clinical value to our customers,” added Matthieu Leclerc-Chalvet, CEO of Therapixel. “Two best-in-class products, MammoScreen and cmAngio, now combine to empower radiologists to work smarter, improve quality and consistency, and make more informed decisions in breast imaging. Improving women’s health and patient outcomes is our mission, and by detecting breast arterial calcifications that often go unnoticed or unreported we are advancing that mission.”

By bringing together two complementary AI platforms, CureMetrix and Therapixel are offering radiology teams an integrated approach that supports earlier detection, better clinical insight, and more comprehensive care for women.